Five things to know ahead of today's opening bell. The Fed will announce its latest interest rate decision. That's coming at 2 PM Eastern time.Investors expecting no change in the federal funds rate, but we will be paying close attention to Fed Chair J Pal's news conference for any clues about the future of rate paths. Elephants Health, formerly known as Anthem, out with its fourth quarter results. Those earnings beat expectations.revenue was a little bit light. Eleance shares though were down 14% yesterday ...

Core Insights - Elevance Health reported a fourth quarter net income of $547 million, reflecting ongoing challenges with healthcare costs impacting earnings [2][3] - The company is the second-largest health insurer in the U.S., operating under the Anthem brand and managing Medicaid contracts [4] Financial Performance - Net income increased by 31% to $547 million, or $2.47 per share, compared to $418 million, or $1.81 per share, in the previous year [8] - Total revenues rose by 9.5% to $49.7 billion, with operating revenue up 10% to $49.3 billion, driven by higher premium yields and growth in Medicare Advantage membership [9][8] Cost and Expense Ratios - The benefit expense ratio increased to 93.5% in the fourth quarter, up from 91.3% in the third quarter, indicating rising medical costs [6][8] - For the full year, the benefit expense ratio was 90.0%, an increase of 150 basis points year-over-year, attributed to elevated medical cost trends [7] Membership and Market Position - Elevance ended 2025 with 45.2 million health plan members, a 1% decrease from the previous year, primarily due to attrition in the Medicaid segment [9] - The company continues to expand its Carelon health services business, with operating revenue increasing by 27% to $18.7 billion [10] Strategic Focus - The CEO emphasized a commitment to improving affordability and access to healthcare, aiming for at least 12% adjusted earnings per share growth by 2027 through pricing discipline and targeted investments [10]

Key TakeawaysElevance Health (ELV) reported a Q4 2025 adjusted EPS of $3.33, exceeding estimates of $3.10, but missed on operating revenue and provided a 2026 adjusted EPS outlook of at least $25.50, below analyst expectations of $26.99.Danaher (DHR) delivered a strong Q4 2025 performance, with sales reaching $6.84 billion (above estimates of $6.79 billion) and adjusted EPS of $2.23 (beating estimates of $2.16), while its 2026 adjusted EPS guidance of $8.35 to $8.50 aligned with estimates.RTX (RTX) received ...

Elevance Health forecast 2026 profit below Wall Street expectations on Wednesday, as the health insurer expects higher medical costs to persist into the year. ...

U.S. stock markets are poised for a pivotal Wednesday, January 28th, 2026, as investors keenly await the Federal Reserve's latest interest rate decision and a flurry of earnings reports from influential technology giants. Premarket trading indicates a mixed but generally upward trend for futures, with the tech-heavy Nasdaq leading the charge, signaling continued optimism in the artificial intelligence (AI) sector.Premarket Activity and Futures MovementsAs the trading day begins to unfold, U.S. stock index f ...

CHONGQING, CHINA - JANUARY 22: In this photo illustration, a smartphone displays the logo of UnitedHealth Group (NYSE: UNH), an American multinational healthcare company providing health insurance services and healthcare solutions through its UnitedHealthcare and Optum businesses, in front of a screen showing the company's latest stock market chart on January 22, 2026, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty ImagesUnitedHealth Group (NYSE: UNH) announced its Q4 2025 earnings ...

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As we enter 2026, our focus is on advancing affordability and making healthcare easier to access and navigate for the members we serve. Through pricing discipline and targeted investments, we are strengthening the earnings power of our diversified platform and ...

Core Insights - Several U.S. politicians sold UnitedHealth stock shortly before a significant market crash on January 27, 2026, raising concerns about the timing of these transactions [1][6][10] Group 1: Stock Performance and Market Impact - UnitedHealth experienced a dramatic loss of approximately 19% in a single trading session, closing at $282.70, which contributed to a nearly 50% decline in its stock value over the past year [2][9] - The company's market capitalization was significantly affected, erasing tens of billions of dollars and dragging down the Dow Jones Industrial Average [1] Group 2: Revenue Guidance and Financial Concerns - UnitedHealth's revenue guidance for 2026 was projected at about $439 billion, falling short of Wall Street estimates of $454 to $456 billion, which contributed to the stock's decline [9] - Rising medical costs and weaker earnings, along with proposed Medicare Advantage payment increases of only 0.09% for 2027, further exacerbated the situation [9] Group 3: Congressional Stock Transactions - Notable transactions included Rep. Kevin Hern selling UnitedHealth shares valued between $250,001 and $500,000 on December 23, 2025, just weeks before the stock's plunge [3][6] - Rep. Julie Johnson sold shares twice in November and December 2025, with each sale ranging from $1,001 to $15,000, occurring while the stock was still perceived as a defensive play [7] - Rep. Gilbert Cisneros sold shares on November 12, 2025, and later purchased shares on December 19, 2025, shortly before the company's outlook worsened [8]

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Elevance became the second major insurer to predict declining revenue in 2026 on Wednesday, as for-profit payers continue to shave off members to try and recover margins. The Indianapolis-based insurer estimated its operating revenue will drop by a low-single digit percentage next year. The guidance comes one day after UnitedHealth forecast an ...

Core Viewpoint - Michael Burry has made a strategic investment shift from UnitedHealth Group to Molina Healthcare, betting on Molina's resilience in the face of regulatory challenges in the healthcare sector [1][3]. Group 1: Investment Strategy - Burry liquidated his stake in UnitedHealth Group in Q3 2025 and heavily invested in Molina Healthcare [1]. - Molina's stock experienced an 8% drop, but it performed better than major competitors like UnitedHealth and Humana, which saw declines of 19% and 21% respectively [2][6]. - Burry's investment in Molina is characterized as a contrarian play, with him labeling it a "generational buy" [3]. Group 2: Financial Performance - Approximately 75% of Molina's revenue is derived from Medicaid, which has allowed the company to maintain profitability despite competitors facing losses in similar contracts [4]. - Molina has demonstrated disciplined operations and conservative accounting practices, contributing to its financial stability [4]. Group 3: Market Position and Future Outlook - Burry's exit from UnitedHealth occurred just before a significant 20% drop in its stock price, indicating timely decision-making [7]. - Molina's stock broke above its 100-day moving average and entered a winning streak, surging over 13% in early January [7]. - Burry has suggested that Molina could be an attractive acquisition target, indicating a strong potential for long-term growth [7].